Patents Assigned to Institute of Molecular Biology
-
Patent number: 10385138Abstract: The present invention relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.Type: GrantFiled: May 31, 2017Date of Patent: August 20, 2019Assignees: Ludwig Institute for Cancer Research Ltd., Sloan-Kettering Cancer Institute, Institute of Molecular Biology and Genetics National Academy of Science of UkraineInventors: Gerd Ritter, Beatrice Yin, Anne Murray, George Mark, Lloyd J. Old, Kenneth Lloyd, Serhiy Souchelnytskiy, Ivan Gout, Valeriy Filonenko, Ramziya Kiyamova
-
Patent number: 9701755Abstract: The present invention relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.Type: GrantFiled: April 22, 2015Date of Patent: July 11, 2017Assignees: Ludwig Institute for Cancer Reserach Ltd., Sloan Kettering Cancer Institute, Institute of Molecular Biology and Genetics National Academy of Science of UkraineInventors: Gerd Ritter, Beatrice Yin, Anne Murray, George Mark, Lloyd J. Old, Kenneth Lloyd, Serhiy Souchelnytskiy, Ivan Gout, Valeriy Filonenko, Ramziya Kiyamova
-
Patent number: 9045533Abstract: The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.Type: GrantFiled: September 26, 2013Date of Patent: June 2, 2015Assignees: Ludwig Institute for Cancer Research Ltd, Institute for Molecular Biology and Genetics National Academy of Science of Ukraine, Sloan Kettering Cancer InstituteInventors: Gerd Ritter, Beatrice Yin, Anne Murray, George Mark, Lloyd J. Old, Kenneth Lloyd, Serhiy Souchelnytskiy, Ivan Gout, Valeriy Filonenko, Ramziya Kiyamova
-
Patent number: 8603474Abstract: The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.Type: GrantFiled: January 29, 2009Date of Patent: December 10, 2013Assignees: Ludwig Institute for Cancer Research, Ltd., Institute of Molecular Biology and Genetics National Academy of Science of Ukraine, Sloan-Kettering Institute for Cancer ResearchInventors: Gerd Ritter, Beatrice Yin, Anne Murray, George Mark, Lloyd Old, Kenneth Lloyd, Serhiy Souchelnytskiy, Ivan Gout, Valeriy Filonenko, Ramziya Kiyamova
-
Publication number: 20030166235Abstract: The present invention relates to nucleic acids comprising a nucleotide sequence encoding at least a portion of an enzyme which catalyzes the synthesis of chitin in arthropods, inhibitors directed to said enzyme, and a method for developing said inhibitors.Type: ApplicationFiled: June 26, 2002Publication date: September 4, 2003Applicant: Foundation for Research and Technology - Hellas Institute of Molecular Biology and BiotechnologyInventors: George Thireos, Dimitris Kafetzopoulos
-
Patent number: 6506727Abstract: It has been found that the growth factor PDGF, when used in combination with another growth factor such as IGF-I, acts synergistically with the other factor to promote neuronal regeneration.Type: GrantFiled: February 18, 1994Date of Patent: January 14, 2003Assignee: Institute of Molecular Biology, Inc.Inventors: Hans-Arne Hansson, Samuel E. Lynch, Harry N. Antoniades
-
Patent number: 6297040Abstract: Disclosed is the DNA sequence of an enzyme which catalyzes the conversion of chitin to chitosan. The enzyme exhibits substantial homology to the rhizobial nodB protein.Type: GrantFiled: July 12, 1999Date of Patent: October 2, 2001Assignee: Institute for Molecular Biology & Biotechnology/FORTHInventors: George Thireos, Dimitri Kafetzopoulos
-
Patent number: 6225121Abstract: Disclosed are isolated transposable elements, or isolated DNA sequences which encode a transposase protein (or a portion of a transposase protein). The isolated transposable elements or the isolated DNA sequences being characterized by the ability to hybridize to the DNA sequence of Minos-1. The invention also relates to a purified transposase protein, or peptide fragments thereof, encoded by such DNA sequences. Such transposable are useful in methods for the stable introduction of a DNA sequence of interest into a cell. The invention further relates to transgenic animals, gene tagging and insertional mutagenesis produced by such methods. The sequence information disclosed herein is useful in the design of oligonucleotide primers which are useful for the isolation of related members of the Tc-1 family of transposable elements.Type: GrantFiled: April 27, 1998Date of Patent: May 1, 2001Assignee: Institute of Molecular Biology and Biotechnology/FORTHInventors: Charalambos Savakis, Gerald H. Franz, Athanasios Loukeris, Apostolos G. Klinakis
-
Patent number: 6159717Abstract: Disclosed are isolated transposable elements, or isolated DNA sequences which encode a transposase protein (or a portion of a transposase protein). The isolated transposable elements or the isolated DNA sequences being characterized by the ability to hybridize to the DNA sequence of Minos-1. The invention also relates to a purified transposase protein, or peptide fragments thereof, encoded by such DNA sequences. Such transposable are useful in methods for the stable introduction of a DNA sequence of interest into a cell. The invention further relates to transgenic animals produced by such methods. The sequence information disclosed herein is useful in the design of oligonucleotide primers which are useful for the isolation of related members of the Tc-1 family of transposable elements.Type: GrantFiled: November 18, 1998Date of Patent: December 12, 2000Assignee: Institute for Molecular Biology and Biotechnology/ForthInventors: Charalambos Savakis, Gerald H. Franz
-
Patent number: 6004795Abstract: Disclosed is the DNA sequence of an enzyme which catalyzes the conversion of chitin to chitosan. The enxyme exhibits substantial homology to the rhizobial nodB protein.Type: GrantFiled: March 25, 1996Date of Patent: December 21, 1999Assignee: Institute for Molecular Biology and BiotechnologyInventors: George Thireos, Dimitri Kafetzopoulos
-
Patent number: 5840865Abstract: Disclosed are isolated transposable elements, or isolated DNA sequences which encode a transposase protein (or a portion of a transposase protein). The isolated transposable elements or the isolated DNA sequences being characterized by the ability to hybridize to the DNA sequence of Minos-1. The invention also relates to a purified transposase protein, or peptide fragments thereof, encoded by such DNA sequences. Such transposable are useful in methods for the stable introduction of a DNA sequence of interest into a cell. The invention further relates to transgenic animals produced by such methods. The sequence information disclosed herein is useful in the design of oligonucleotide primers which are useful for the isolation of related members of the Tc-1 family of transposable elements.Type: GrantFiled: September 20, 1995Date of Patent: November 24, 1998Assignee: Institute of Molecular Biology and Biotechnology/FORTHInventors: Charalambos Savakis, Gerald H. Franz, Athanasios Loukeris
-
Patent number: 5656605Abstract: The invention relates generally to a system for promoting regeneration of a damaged nerve. In particular, the invention comprises: (1) a guide tube constructed to be attached to the damaged nerve; (2) guiding filaments disposed within the guide tube; and, (3) a therapeutic composition enclosed by the guide tube. Both the guide tube and the guiding filaments are composed of biologically compatible materials, while the therapeutic composition contains a nerve-growth-stimulating agent dispersed in a matrix-forming material. During treatment, the guide tube is inserted between the ends of lesioned nerves, resulting in the stimulation of axon growth.Type: GrantFiled: January 26, 1994Date of Patent: August 12, 1997Assignee: Institute of Molecular Biology, Inc.Inventors: Hans-Arne Hansson, Michael R. Wells, Samuel E. Lynch, Harry N. Antoniades
-
Patent number: 5569582Abstract: Disclosed herein are methods, primers, probes, and kits for the rapid amplification and detection of nucleic acids. The invention provides improved methods for amplifying small amounts of nucleic acid in a sample in which the amplification steps are conducted at the same temperature, or alternatively, at two different temperatures. The invention also provides improved methods for detecting the amplified nucleic acid in which the detection signal is boosted. Related probes and test kits are also provided. The invention is particularly useful in the detection of HIV-1.Type: GrantFiled: December 22, 1993Date of Patent: October 29, 1996Assignee: Institute of Molecular Biology & TechnologyInventors: Nectarios Tavernarakis, George Hatzidakis, Elias Krambovitis
-
Patent number: 5525502Abstract: Disclosed is the DNA sequence of an enzyme which catalyzes the conversion of chitin to chitosan. The enxyme exhibits substantial homology to the rhizobial nodB protein.Type: GrantFiled: December 7, 1992Date of Patent: June 11, 1996Assignee: Institute for Molecular Biology & Biotechnology/FORTHInventors: George Thireos, Dimitri Kafetzopoulos
-
Patent number: 5516699Abstract: A method of diagnosing severity of periodontal disease or peri-implant disease in a human patient, involving a) obtaining a sample of tissue or gingival crevicular or other fluid from the mouth of said patient, or a blood or urine sample from the patient, and b) measuring a pyridinoline crosslinked compound in the sample as a measure of severity of disease.Type: GrantFiled: February 16, 1994Date of Patent: May 14, 1996Assignees: Institute of Molecular Biology, Inc., President and Fellows of Harvard CollegeInventors: William V. Giannobile, Ray C. Williams, Samuel E. Lynch
-
Patent number: 5348874Abstract: Disclosed are isolated transposable elements, or isolated DNA sequences which encode a transposase protein (or a portion of a transposase protein). The isolated transposable elements or the isolated DNA sequences being characterized by the ability to hybridize to the DNA sequence of Minos 1 under stringent hybridization conditions. The invention also relates to a purified transposase protein, or peptide fragments thereof, encoded by such DNA sequences. Such transposable are useful in methods for the stable introduction of a DNA sequence of interest into a eukaryotic cell. The sequence information disclosed herein is useful in the design of oligonucleotide primers which are useful for the isolation of related members of the Tc-1 family of transposable elements.Type: GrantFiled: September 14, 1992Date of Patent: September 20, 1994Assignee: Institute for Molecular Biology and Biotechnology/FORTHInventors: Charalambos Savakis, Gerald H. Franz, Athanasios Loukeris
-
Patent number: 5256644Abstract: Healing an external wound of a mammal by administering to the mammal a composition containing purified Insulin-like growth factor-I and purified transforming growth factor beta.Type: GrantFiled: March 25, 1992Date of Patent: October 26, 1993Assignees: Institute of Molecular Biology, Inc., President and Fellows of Harvard CollegeInventors: Harry N. Antoniades, Samuel E. Lynch
-
Patent number: 5219749Abstract: Chitin deacetylase, the enzyme that catalyzes the hydrolysis of acetamide groups of N-acetylglucosamine in chitin, was purified to homogeneity from mycelial extracts of the fungus Mucor rouxii. In addition, immunoglobulin specifically reactive with chitin deacetylase has been produced and purified.Type: GrantFiled: October 9, 1991Date of Patent: June 15, 1993Assignee: Institute for Molecular Biology & Biotechnology/FORTHInventors: Vassilis Bouriotis, Dimitri Kafetzopoulos, John Vournakis
-
Patent number: 5124316Abstract: A method for promoting bone, periodontium or ligament growth of a mammal comprising applying to the bone periodontium or ligament a growth-promoting amount of a composition comprising a partially purified or purified polypeptide growth factor.Type: GrantFiled: September 13, 1990Date of Patent: June 23, 1992Assignees: President and Fellows of Harvard College, Institute of Molecular Biology, Inc.Inventors: Harry N. Antoniades, Samuel E. Lynch
-
Patent number: 5034375Abstract: Healing an external wound of a mammal by administering to the mammal a composition containing purified EGF and purified PDGF in a weight to weight ratio of at least 5:1.Type: GrantFiled: August 10, 1988Date of Patent: July 23, 1991Assignees: Institute of Molecular Biology, Inc., President and Fellows of Harvard CollegeInventors: Harry N. Antoniades, Samuel E. Lynch